GE’s Cardiovascular Ultrasound Gets FDA Nod
The Vivid E9 Breakthrough 2012 includes a 4-D transducer for transesophageal echocardiography, as well as workflow tools.
GE Healthcare’s latest Vivid E9 cardiovascular ultrasound has received FDA clearance, the company announced.
The Vivid E9 Breakthrough 2012 includes a 4-D transducer for transesophageal echocardiography (TEE), as well as tools for workflow efficiencies.
The 4-D TEE transducer allows the system to be used more often in settings beyond the echo lab, the company said. Clinicians can view precise images of the heart during assessment and diagnosis in the echo lab, as well as support procedures in the operating room and cath lab. The system can now be used for procedures such as mitral valve repair, transcatheter aortic valve repair, atrial septal defect closures and patent foraman ovale closures.
The Vivid E9 BT12 also includes several new cardiovascular ultrasound features aimed at improving 4-D imaging and workflow, such as a new tilt and rotate function. Vivid E9 BT12 is also CE Marked and available for sale across Europe and many countries around the world.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
